GET DAILY SIGNALSWhy Is Castle Biosciences (CSTL) Stock Down -5.56% Today?
Key Takeaways
- CSTL fell 5.56% to $32.30, down from the prior session's close of $34.20.
- The decline extends a post-earnings "sell the news" reaction despite a third-quarter revenue beat and a raised full-year outlook.
- Investors are focusing on a softening dermatology franchise and delayed reimbursement catalysts rather than the headline results.
- The raised guidance implies fourth-quarter revenue roughly flat to down sequentially, tempering enthusiasm around near-term growth.
- Traders are watching upcoming CMS pricing decisions and reimbursement developments for key tests.
- Get more details on Price Targets, Earnings, and Forecast for CSTL on Tickeron's dedicated pages.
- Explore Trending AI Robots to see which automated strategies are performing best in current market conditions.
Opening Summary
Castle Biosciences, Inc. (CSTL), a molecular diagnostics company focused on dermatologic cancers and gastroenterological disease, saw its shares fall sharply in Thursday's session. The stock traded down 5.56% to $32.30, compared with a prior close of $34.20, extending losses that began immediately after the company reported third-quarter results. The move reflects investor disappointment over forward-looking details buried beneath an otherwise strong headline report, even as the company beat revenue estimates and lifted its full-year guidance.
Earnings Beat and Raised Guidance
Castle Biosciences reported third-quarter revenue of $102.9 million, up 24% year over year and well above consensus estimates near $92 million to $94 million. The company posted a net loss of $0.13 per share, narrower than the roughly $0.35 to $0.38 loss analysts had expected, and adjusted EBITDA rose to $12.7 million from $9.2 million a year earlier. Management also raised its full-year 2026 revenue guidance to a range of $385 million to $395 million, up from $365 million to $375 million, marking a third consecutive increase.
Despite these positive headline figures, the market reaction was muted and ultimately negative. A major contributor was the TissueCypher Barrett's Esophagus test, whose report volume jumped 47% year over year to 15,574. However, that growth is decelerating against tougher comparisons, and management flagged rising seasonality heading into the fourth quarter.
Why Shares Fell: Softening Dermatology and Sequential Deceleration
Beneath the top-line strength, investors homed in on signs of strain across Castle's legacy dermatology portfolio. DecisionDx-Melanoma reports slipped to 10,177 from 10,459 a year earlier, prompting the company to trim its full-year growth outlook for the test to mid-single digits. DecisionDx-SCC reports fell 7%, and MyPath Melanoma reports dropped 31%, underscoring that much of the quarter's growth now rests on a single product.
The guidance raise also implied a fourth quarter near $100 million in revenue, essentially flat to down from the third quarter, with management assuming flat average selling prices. That sequential pause, combined with rising operating expenses and a widened net loss of $4.1 million, gave investors reasons to take profits after the stock's substantial run-up following its July report.
Reimbursement Uncertainty Weighs on Sentiment
Two reimbursement catalysts also slipped, adding to the bearish tilt. The Centers for Medicare and Medicaid Services proposed gapfill pricing for the AdvanceAD-Tx atopic dermatitis test rather than the crosswalk pricing an advisory panel had recommended, with a final decision expected in early December. Separately, a hoped-for draft local coverage determination restoring Medicare coverage for DecisionDx-SCC has been delayed, with management now assuming no SCC Medicare revenue in 2027. These regulatory overhangs kept commercial focus narrow and contributed to the risk-off tone in the shares.
Market Context and Trading Activity
Trading volume was elevated around the earnings release, with the prior session logging more than 332,000 shares versus a roughly 190,000 to 269,000 average in the preceding days, signaling active repositioning. The selloff reflects company-specific dynamics rather than broad sector weakness, as investors reassessed the durability of test volume growth and the timeline for reimbursement clarity. Technically, the stock has now surrendered a meaningful portion of its post-July rally and moved further below levels it held heading into the report.
What Comes Next for CSTL
Looking ahead, traders will focus on the December CMS pricing decision for AdvanceAD-Tx and any progress on the DecisionDx-SCC Medicare coverage timeline. Upcoming quarterly results will test whether TissueCypher volume growth can sustain its momentum and whether the dermatology franchise stabilizes. Management reiterated expectations for positive adjusted EBITDA in the fourth quarter, full-year 2026, and 2027, supported by a cash position of roughly $277.7 million. Risks remain, including reimbursement uncertainty, competitive pressures in diagnostics, and the concentration of growth in a single test.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, helping traders identify strategies that have adapted well to shifting market environments. Explore Trending AI Robots to discover automated approaches that may align with your trading objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CSTL in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for CSTL crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CSTL advanced for three days, in 232 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 203 of 227 cases where CSTL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for CSTL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 32 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CSTL as a result. In 70 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for CSTL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 36 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CSTL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
CSTL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.114) is normal, around the industry mean (67.298). P/E Ratio (-50.812) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.947) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CSTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients.
Industry MedicalSpecialties
Advertisement